Last updated on February 2020

To Evaluate the Safety and Tolerability of Atogepant 10mg 30 mg and 60 mg Once a Day for the Prevention of Migraine in Participants With Episodic Migraine

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Episodic Migraine
  • Age: Between 18 - 80 Years
  • Gender: Male or Female

Inclusion Criteria:

  • At least a 1-year history of migraine with or without aura consistent with a diagnosis.
  • Age of the participant at the time of migraine onset < 50 years.

Exclusion Criteria:

  • Has a history of migraine accompanied by diplopia or decreased level of consciousness or retinal migraine
  • Has a current diagnosis of chronic migraine, new persistent daily headache, trigeminal autonomic cephalgia (eg, cluster headache), or painful cranial neuropathy
  • History of an inadequate response to > 4 medications (2 of which have different mechanisms of action) prescribed for the prevention of migraine
  • Participants with clinically significant hematologic, endocrine, cardiovascular, pulmonary, renal, hepatic, gastrointestinal, or neurologic disease.

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.